Rodman & Renshaw analyst Brandon Folkes initiates coverage on Cormedix (NASDAQ:CRMD) with a Buy rating and announces Price Target of $13.
Rodman & Renshaw Initiates Coverage On Cormedix With Buy Rating, Announces Price Target of $13
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.